A former star Goldman Sachs pharma analyst just made her first deal with AbbVie’s $63 billion bid for Botox-maker Allergan. Meet the bankers involved in the megamerger.
|06/25/2019||Posted by BusinessMediaguide.Com under General World News||
- AbbVie is buying Botox-maker Allergan in a $63 billion deal, the companies said on Tuesday.
- The deal would combine AbbVie, which makes the blockbuster drug Humira, with Allergan, which has been facing pressure from activists for more than a year to improve performance.
- Bankers from Morgan Stanley and PJT Partners, including former Goldman Sachs analyst Jami Rubin, advised AbbVie on the transaction, while JPMorgan advised Allergan.
- Click here for more BI Prime stories.
Another massive pharmaceutical merger is underway.